tirzepatide cardiovascular trial Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT In patients with type 2

Ipamorelin and reproductive hormone support connection on how the body manages growth and fertility

doi: 10.2337/diabetes.52.2.380 63 CoskunTSloopKWLoghinCAlsina-FernandezJUrvaSBokvistKBet al

The above study from Diabetes Obesity Metabolism said: The average change in body weight was similar in the two groups (-3.7 kg with injectable and -3.3 kg with oral at 18 months), but more new users of injectable semaglutide lost 5% body weight. According to Dr

Which foods should I avoid to stop sulfur burps

doi: 10.1038/cr.2016.27 304 QiuT.LiuQ.ChenY.-X.ZhaoY.-F.LiY.-M

Tirzepatide is a dual GIP/GLP-1 receptor agonistmeaning it activates both the glucose-dependent insulinotropic polypeptide pathway and the GLP-1 pathway simultaneously